Table 1. Median fluorescence intensity (MFI) of CD86 and MHC class II on CD19⁺ or CD11c⁺ cells in draining lymph nodes post Matrix-M™ treatment.

Lymph nodes		CD86 (×103)		MHC class II (×103)
		24 h	48 h	24 h	48 h
CD19	PBS	0.8±0.05	0.8±0.1	42±5	47±4
	Matrix-M™ 3 µg	1.7±0.8	1.9±0.6**	41±4	49±3
	Matrix-M™ 12 µg	2.8±0.3***	1.8±0.4*	51±7*	44±4
	Matrix-M™ 30 µg	2.4±0.3***	2.2±0.5***	42±5	50±5
CD11c	PBS	7.9±2.7	12±6.9	103±35	124±49
	Matrix-M™ 3 µg	19±8.6	9.5±3.5	128±37	67±39
	Matrix-M™ 12 µg	54±13***	9.8±2.2	208±35***	56±21*
	Matrix-M™ 30 µg	42±11***	15±8.2	187±37***	60±30*

Mice were injected subcutaneously at the base of the tail and the draining lymph nodes were harvested and analyzed as described in Materials and Methods. Data is shown as mean ± SD (n = 6–8 mice). Significant differences from PBS treatment using Kruskal-Wallis test with Dunn's posttest are outlined with *, p<0.05; **, p<0.01; ***, p<0.001.